Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rcdtf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) measures how much investors pay for each dollar of the company's trailing earnings. RCDTF's current PE ratio of 21.94x is calculated by dividing its stock price of $60.00 by its TTM earnings per share of $2.31. −15.6% discount vs 5Y avg 26.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%20.7x
MedianQ3 · 75%30.0x
Max
At 21.94x, RCDTF's current P/E is within its average historical range over the past 20 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Recordati Industria Chimica e Farmaceutica S.p.A.You RCDTF | $12.2B | 21.94x | -61.0% | $2.31 |
 Bangkok Dusit Medical Services Public Company Limited BDULF | $8.8B | 19.24x | -65.8% | $1.00 |
 Bangkok Dusit Medical Services Public Company Limited BDUUF | $9.5B | 18.66x | -66.8% | $1.00 |
 Swedish Orphan Biovitrum AB (publ) BIOVF | $16.4B | 234.66x | +317.5% | $1.38 |
 CSPC Pharmaceutical Group Limited CHJTF | $12.0B | 22.34x | -60.3% | $0.33 |
 CSPC Pharmaceutical Group Limited CSPCY | $10.5B | 25.38x | -54.9% | $1.32 |
 Grifols, S.A. GIFLF | $7.6B | 16.98x | -69.8% | $0.58 |
Industry Average 6 peers with valid PE | — | 56.21x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 25.91x | $2.15 | -2.5% | |
2024-12-31 FY2024 | 26.57x | $2.02 | +18.8% | |
2023-12-31 FY2023 | 22.36x | $1.86 | -11.1% | |
2022-12-31 FY2022 | 25.16x | $1.52 | -16.2% | |
2021-12-31 FY2021 | 30.02x | $1.87 | +15.6% | |
2020-12-31 FY2020 | 25.97x | $1.73 | +29.7% | |
2019-12-31 FY2019 | 20.02x | $1.80 | -6.1% | |
2018-12-31 FY2018 | 21.32x | $1.53 | -15.0% | |
2017-12-31 FY2017 | 25.08x | $1.39 | -4.0% | |
2016-12-31 FY2016 | 26.14x | $1.15 | +7.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) measures how much investors pay for each dollar of the company's trailing earnings. RCDTF's current PE ratio of 21.94x is calculated by dividing its stock price of $60.00 by its TTM earnings per share of $2.31.
Frequently asked questions
RCDTF pe ratio · 6 questionsRCDTF's current PE ratio is 21.94x as of 2026-06-09, based on a stock price of $60.00 and TTM EPS of $2.31. Data sourced from Financial Modeling Prep via RCDTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Recordati Industria Chimica e Farmaceutica S.p.A. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09